An IV fluid infusion pump is a regulated medical device that delivers fluids into a patient in a controlled manner. The FDA identifies the device under 21 CFR 880.5725 as intended for use in a health care facility, and it may use a piston pump, roller pump, or peristaltic pump powered electrically or mechanically [1][3]. The device may also detect fault conditions such as air in the infusion line or blockage and activate an alarm [3]. For procurement and clinical engineering teams, the practical question is not simply which pump to buy, but how to distinguish device categories, assess documented failure modes, and build an evaluation process that reflects the total product life cycle. This guide addresses those decision points using primary FDA documentation and ISMP safety guidance, while identifying what the available evidence cannot establish.

Regulatory Scope and Device-Category Distinctions

The FDA guidance for infusion pumps applies to class II devices classified under 21 CFR 880.5725, including the product codes listed in the guidance. Those product codes include FRN for infusion pump, MEA for patient controlled analgesia pump, MEB for elastomeric infusion pump, LZG for insulin infusion pump, OPP for insulin bolus infusion pump, LZH for enteral infusion pump, MRZ for infusion pump accessories, and PHC for infusion safety management software [1]. Devices submitted as part of a class III system follow the premarket approval application pathway rather than the 510(k) pathway [1]. The guidance notes that not all items recommended for a 510(k) submission would be relevant to a PMA submission, and additional items may be required for a PMA that would not be required as part of a 510(k) submission [1].

The FDA defines the infusion pump system more broadly than the pump hardware alone. The system includes the infusion pump and the fluid infusion set for the complete fluid pathway from, and including, the drug reservoir or fluid source container, infusion set, extension sets, filters and valves, clamps, up to and including the patient connection [1]. This system definition matters for evaluation because a failure in any connected component can affect delivery. The FDA guidance states that, within the framework of the superseded 2005 software guidance, infusion pumps were considered a device with a Major Level of Concern. Under the final 2023 guidance "Content of Premarket Submissions for Device Software Functions," infusion pumps should generally address the recommendations for an Enhanced Documentation Level, though the actual Documentation Level may vary based on the specifics of the device [1]. The purpose of the Documentation Level is to help identify the minimum amount of information that would support a premarket submission that includes device software functions [1].

Documented Failure Modes and Safety Context

The most frequently reported infusion pump device problems include software error messages, human factors issues such as use error related to instructions for use, training, and other user interface issues, broken components, battery failure, alarm failure, and over infusion and under infusion [2]. In some reports, the manufacturer could not determine the problem and reported it as unknown. Subsequent analyses revealed that many of these were related to design problems that could be corrected during the design processes [2]. These findings indicate that evaluation should examine design documentation and failure reporting, not only the device specification sheet.

FDA adverse event data provide a broader safety context. From 2005 through 2009, FDA received approximately 56,000 reports of adverse events associated with the use of infusion pumps, including numerous injuries and deaths. During that period, manufacturers conducted 87 infusion pump recalls to address identified safety concerns. Seventy of those recalls were designated as Class II, a category that applies when the use of the recalled device may cause temporary or medically reversible adverse health consequences, or when the probability of serious adverse health consequences is remote. Fourteen recalls were Class I, situations in which there is a reasonable probability that use of the recalled device will cause serious adverse health consequences or death [4]. These figures describe a historical reporting window and do not establish current failure rates for any specific model.

Risk Reduction Practices for Clinicians

FDA risk reduction strategies include having a back-up plan for infusion pump failure, labeling pump channels and tubing with the medication or fluid name, verifying programmed dosage and rate, and obtaining an independent double-check of settings for high-risk medications [7]. Clinicians are also advised to remove from use, tag, and sequester any pump that shows signs of breakage or damage, produces an unexplained alarm, or does not function as expected [7]. The FDA states that these strategies are not applicable to all types of infusion pumps in all clinical settings and patient populations, and they do not replace facility policy or manufacturer instructions [7].

Smart Pump Dose-Error Reduction Systems

A smart pump is equipped with safety features such as user alerts that activate when there is a risk of an adverse drug interaction or when the user sets parameters outside specified safety limits [5]. ISMP defines dose error-reduction systems, or DERS, as the integral computer software in smart infusion pumps intended to aid in prevention of infusion programming-related errors and warn users of potential over- or under-delivery of a medication or fluid by checking programmed doses or rates against facility-configurable preset limits specific to a medication or fluid, and to a clinical application or location [6]. If the programmed dose is outside preset limits, the pump alerts clinicians and can either require confirmation before beginning delivery, described as a soft limit, or not allow delivery at all, described as a hard limit [6].

ISMP guidance states that use of smart infusion pump technology is expected practice throughout the organization, including ambulatory settings such as perioperative, procedural, and radiology areas, the emergency department, and infusion centers for the administration of medication infusions and all IV fluid infusions [6]. The guidance also notes that smart infusion pumps with an IV Fluid, No Drug library entry could allow users to select that choice to administer a medication infusion and still be considered compliant with using DERS [6]. This distinction is relevant when evaluating whether a pump library supports the intended clinical workflows.

A Hypothetical Evaluation Workflow

A procurement team could structure an evaluation around the FDA total product life cycle guidance and ISMP infrastructure recommendations. One suggested workflow is to first map the intended use environment, routes of administration, specific uses, and indicated treatment population for each candidate pump [2]. The team would then request documentation for the pump system, including the fluid pathway components, rather than reviewing the pump as an isolated device [1]. This step helps identify whether accessories and software are covered by the same regulatory submission.

A second suggested step is to test the DERS library configuration against the organization's actual IV fluid and medication orders. The team could create a small set of representative orders, including continuous infusions, intermittent and secondary infusions, IV bolus and loading dose infusions, PCA infusions, and epidural and nerve block infusions [6]. For each order, the team would verify whether the pump can enforce soft or hard limits and whether the library includes an IV Fluid, No Drug entry that could be misused for a medication infusion [6]. This workflow is a suggestion for evaluation planning and does not constitute a validated testing protocol.

What the Evidence Cannot Establish

The available primary documentation does not provide comparative performance data for specific commercial IV fluid infusion pump models. FDA guidance describes recommended documentation and product codes, but it does not rank devices or certify that any particular pump is safer than another [1][2]. The adverse event counts from 2005 through 2009 are historical and cannot be used to infer current model-level reliability [4]. Procurement teams should not treat the absence of a reported problem in a public database as proof that a device has no failure history.

The ISMP guidelines describe expected practices and definitions, but they do not provide clinical outcome data showing that smart pump use reduces patient harm in a specific facility [6]. The FDA risk reduction strategies for clinicians include planning ahead, labeling, checking, and reporting problems, but the agency states that these strategies are not applicable to all types of infusion pumps in all clinical settings and patient populations [7]. Any conclusion that a particular pump or workflow improves clinical outcomes would require evidence beyond the public documents.